Novavax reported second-quarter 2026 revenue of US$56.7 million and a net loss of US$53.39 million, beating analyst expectations for both revenue and earnings despite sharp year-on-year declines. The company highlighted progress on partnerships with Sanofi and Pfizer, while also filing an US$82.47 million employee stock offering shelf registration. The results underscore Novavax's reliance on milestone and royalty income from its Matrix M adjuvant and partnered vaccine portfolio as standalone sales remain weak.
Novavax IncBeat Q2 revenue and earnings estimates, though year-on-year declines and reliance on partnerships noted.
Pfizer Inc
Sanofi SA